COMMUNIQUÉS West-GlobeNewswire

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
10/02/2026
Protocol Expansion Broadens Phase 3 HERO Trial Eligibility Criteria to Include Children Ages 7+ in the United States SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a [...]
FibroBiologics’ Chairman & CEO Pete O’Heeron Selected to Present at A4LI’s H-SPAN Summit at Georgetown University
10/02/2026
HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era
10/02/2026
The new partnership combines Weight Watchers’ scientifically-backed medical and behavioral expertise with PVOLVE’s clinically-studied method to support members at every age and stage of life NEW YORK, Feb. 10, 2026 ( [...]
Imprivata Introduces Advanced Access Management and Passwordless Authentication Capabilities to Improve User Efficiency and Strengthen Security
10/02/2026
Tailored for all users and workflows, Imprivata Enterprise Access Management now offers context-aware passwordless authentication, advanced biometrics, and AI-powered behavioral analytics to further streamline access to [...]
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
10/02/2026
Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0. [...]
PathAI Expands AISight® Clinical Trials Platform with Launch of AIM-HI™ UC and IBDExplore™ for Standardized Histopathology Endpoints
10/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, today announced the strategic expansion of its support of inflammatory bowel disease clinical trials on the AISight® Clinical [...]
VirtuAlly Among First in Nation to Deliver Specialized Virtual Nursing in Neonatal Intensive Care Setting
10/02/2026
Partnership with MUSC brings virtual nursing to South Carolina’s highest-acuity NICU. CHARLESTON, S.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- VirtuAlly , a national leader in virtual nursing (VRN) and clinical support [...]
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
10/02/2026
Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting [...]
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephology (JASN)
10/02/2026
MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 ST. LOUIS, Feb [...]
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
10/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today [...]
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
10/02/2026
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli will lead the [...]
Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™
10/02/2026
Kennewick, WA, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT ™ ) with its innovative RadioGel ® technology, today provided an [...]
Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure
10/02/2026
CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s [...]
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
10/02/2026
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval process and reduce [...]
Survey Reveals the Hidden Mental & Social Burden of Managing Celiac Disease
10/02/2026
More than half of people with celiac say they feel isolated or excluded; a majority admit they avoid restaurants and family gatherings just to prevent accidental gluten exposure BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE [...]
Health Canada cannabis guidance exposes “absurd” education gap in healthcare
10/02/2026
- Apothecare calls for medical cannabis education to be integrated into clinical training and standard practice, not left to patients to figure out on their own - TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- New federal [...]
Practicing Excellence Acquires Sageful AI to Accelerate Scalable Behavior Change Across Healthcare
10/02/2026
Combined organization strengthens personalized, in-workflow coaching aligned to organizational priorities SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Practicing Excellence , the leading platform for technology-powered [...]
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
10/02/2026
The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) [...]
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
10/02/2026
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for [...]

Pages